Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2014

Open Access 01-12-2014 | Research

Khat chewing and health related quality of life: cross-sectional study in Jazan region, Kingdom of Saudi Arabia

Authors: Kamaludin Ahmed Sheikh, Maged El-setouhy, Umar Yagoub, Rashad Alsanosy, Zafar Ahmed

Published in: Health and Quality of Life Outcomes | Issue 1/2014

Login to get access

Abstract

Background

The chewing of Khat leaves, a natural psychoactive substance is widely chewed in countries of East Africa and the southern Arabian Peninsula, and is reported to be associated with a range of unfavorable health outcomes including khat dependence. The impact of Khat chewing on Health Related Quality of Life is yet to be explored. Aims: to measure and compare the quality of life of the khat chewers and non-khat chewers using a short form health survey (SF36), and to assess factors associated with Khat chewing using SF36 in a sample of adult population in Jazan region, Kingdom of Saudi Arabia.

Methods

A total of 630 participants from two independent male populations of khat chewers and non-khat chewers were recruited into a cross-sectional survey study. A self administrative survey based on the SF-36 questionnaire was used to collect data on measures of health-related quality of life (HRQoL). Socioeconomic data of the respondents were also collected for detailed analysis. Data analysis include: descriptive statistics, reliability tests (Cronbach’s alpha and intraclass correlation coefficient), and bivariate analysis (Chi square and Mann–Whitney U-test) to compare HRQoL of Khat chewers and non-Khat chewers.

Results

The odds of being a khat chewer were higher in respondents with a lower socioeconomic status. The SF-36 scores were significantly lower in all domains for respondents with khat chewing, indicating that non-khat chewers had higher health perceptions compared with those chewing khat. The overall mean score of HRQoL for non-khat chewers was 92.7% (SD 5.53) compared with 63.5% (SD 21.73) for the khat chewing group. The study had shown good internal consistency and reproducibility across the eight subscales of SF-36 questionnaire (α 0.74-0.95). The Mann–Whitney U-test showed a significant difference between khat chewers and non-khat chewers (P < 0.001).

Conclusions

This study measured and compared the quality of life of khat chewers and non-khat chewers using a generic health survey (SF36). The study had shown that khat chewing is associated with lower quality of life (HRQoL) and lower socioeconomic status. However in future a more refined SF36 developed especially for Khat chewers can provide more useful information.
Appendix
Available only for authorised users
Literature
1.
Gebissa E: Khat in the Horn of Africa: historical perspectives and current trends. J Ethnopharmacol 2010, 132: 607–614. 10.1016/j.jep.2010.01.063CrossRefPubMed
2.
Luqman W, Danowski TS: The use of khat (Catha edulis) in Yemen. Social and medical observations. Ann Intern Med 1976, 85: 246–249. 10.7326/0003-4819-85-2-246CrossRefPubMed
3.
Dhaifalah I, Santavy J: Khat habit and its health effect. A natural amphetamine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004, 148: 11–15. 10.5507/bp.2004.002CrossRefPubMed
4.
5.
Griffiths P, Lopez D, Sedefov R, Gallegos A, Hughes B, Noor A, Royuela L: Khat use and monitoring drug use in Europe: the current situation and issues for the future. J Ethnopharmacol 2010, 132: 578–583. 10.1016/j.jep.2010.04.046CrossRefPubMed
6.
Pennings EJ, Opperhuizen A, van Amsterdam JG: Risk assessment of khat use in the Netherlands: a review based on adverse health effects, prevalence, criminal involvement and public order. Regul Toxicol Pharmacol 2008, 52: 199–207. 10.1016/j.yrtph.2008.08.005CrossRefPubMed
7.
Al-Samarraie M, Khiabani HZ, Opdal MS: Khat–a new drug of abuse in Norway. Tidsskr Nor Laegeforen 2007, 127: 574–576.PubMed
8.
Klein A: Khat in the neighbourhood–local government responses to khat use in a London community. Subst Use Misuse 2008, 43: 819–831. 10.1080/10826080701738976CrossRefPubMed
9.
Osman FA, Soderback M: Perceptions of the use of khat among Somali immigrants living in Swedish society. Scand J Public Health 2011, 39: 212–219. 10.1177/1403494810384908CrossRefPubMed
10.
Stefan J, Mathew B: Khat chewing: an emerging drug concern in Australia? Aust N Z J Psychiatry 2005, 39: 842–843.CrossRefPubMed
11.
Douglas H, Boyle M, Lintzeris N: The health impacts of khat: a qualitative study among Somali-Australians. Med J Aust 2011, 195: 666–669. 10.5694/mja11.10166CrossRefPubMed
12.
Douglas H, Pedder M: Legal regulation of the drug khat in Australia. J Law Med 2010, 18: 284–301.PubMed
13.
Kroll J, Yusuf AI, Fujiwara K: Psychoses, PTSD, and depression in Somali refugees in Minnesota. Soc Psychiatry Psychiatr Epidemiol 2011, 46: 481–493. 10.1007/s00127-010-0216-0CrossRefPubMed
14.
Chappell JS, Lee MM: Cathinone preservation in khat evidence via drying. Forensic Sci Int 2010, 195: 108–120. 10.1016/j.forsciint.2009.12.002CrossRefPubMed
15.
Laussmann T, Meier-Giebing S: Forensic analysis of hallucinogenic mushrooms and khat (Catha edulis Forsk) using cation-exchange liquid chromatography. Forensic Sci Int 2010, 195: 160–164. 10.1016/j.forsciint.2009.12.013CrossRefPubMed
16.
Hagel JM, Krizevski R, Kilpatrick K, Sitrit Y, Marsolais F, Lewinsohn E, Facchini PJ: Expressed sequence tag analysis of khat (Catha edulis) provides a putative molecular biochemical basis for the biosynthesis of phenylpropylamino alkaloids. Genet Mol Biol 2011, 34: 640–646.PubMedCentralPubMed
17.
Belhadj-Tahar H, Sadeg N: Methcathinone: a new postindustrial drug. Forensic Sci Int 2005, 153: 99–101. 10.1016/j.forsciint.2005.04.023CrossRefPubMed
18.
Al-Akwa AA, Shaher M, Al-Akwa S, Aleryani SL: Free radicals are present in human serum of Catha edulis Forsk (Khat) abusers. J Ethnopharmacol 2009, 125: 471–473. 10.1016/j.jep.2009.07.012CrossRefPubMed
19.
Kalix P: Catha edulis, a plant that has amphetamine effects. Pharm World Sci 1996, 18: 69–73. 10.1007/BF00579708CrossRefPubMed
20.
Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU: Pharmacodynamics and pharmacokinetics of khat: a controlled study. Clin Pharmacol Ther 1994, 55: 556–562. 10.1038/clpt.1994.69CrossRefPubMed
21.
Adeoya-Osiguwa SA, Fraser LR: Cathine and norephedrine, both phenylpropanolamines, accelerate capacitation and then inhibit spontaneous acrosome loss. Hum Reprod 2005, 20: 198–207.CrossRefPubMed
22.
Al-Habori M: The potential adverse effects of habitual use of Catha edulis (khat). Expert Opin Drug Saf 2005, 4: 1145–1154. 10.1517/14740338.4.6.1145CrossRefPubMed
23.
Ali WM, Zubaid M, Al-Motarreb A, Singh R, Al-Shereiqi SZ, Shehab A, Rashed W, Al-Sagheer NQ, Saleh AH, Al Suwaidi J: Association of khat chewing with increased risk of stroke and death in patients presenting with acute coronary syndrome. Mayo Clin Proc 2010, 85: 974–980. 10.4065/mcp.2010.0398PubMedCentralCrossRefPubMed
24.
Balint EE, Falkay G, Balint GA: Khat - a controversial plant. Wien Klin Wochenschr 2009, 121: 604–614. 10.1007/s00508-009-1259-7CrossRefPubMed
25.
Getahun W, Gedif T, Tesfaye F: Regular Khat (Catha edulis) chewing is associated with elevated diastolic blood pressure among adults in Butajira, Ethiopia: a comparative study. BMC Public Health 2010, 10: 390. 10.1186/1471-2458-10-390PubMedCentralCrossRefPubMed
26.
27.
28.
Ali WM, Al Habib KF, Al-Motarreb A, Singh R, Hersi A, Al Faleh H, Asaad N, Al Saif S, Almahmeed W, Sulaiman K, Amin H, Al-Lawati J, Al Bustani N, Al-Sagheer NQ, Al-Qahtani A, Al Suwaidi J: Acute coronary syndrome and khat herbal amphetamine use: an observational report. Circulation 2011, 124: 2681–2689. 10.1161/CIRCULATIONAHA.111.039768CrossRefPubMed
29.
Oyungu E, Kioy PG, Patel NB: Effect of Catha edulis (khat) on behaviour and its potential to induce seizures in Sprague Dawley rats. East Afr Med J 2007, 84: 219–225.PubMed
30.
Toennes SW, Kauert GF: Driving under the influence of khat–alkaloid concentrations and observations in forensic cases. Forensic Sci Int 2004, 140: 85–90. 10.1016/j.forsciint.2003.11.028CrossRefPubMed
31.
Numan N: Exploration of adverse psychological symptoms in Yemeni khat users by the Symptoms Checklist-90 (SCL-90). Addiction 2004, 99: 61–65. 10.1111/j.1360-0443.2004.00570.xCrossRefPubMed
32.
Al-Sanosy RM: Pattern of khat abuse and academic performance among secondary school and college students in Jazan region, kingdom of Saudi Arabia (KSA). J Fam Community Med 2009, 16: 89.
33.
Ageely HM: Prevalence of Khat chewing in college and secondary (high) school students of Jazan region, Saudi Arabia. Harm Reduct J 2009, 6: 11. 10.1186/1477-7517-6-11PubMedCentralCrossRefPubMed
34.
Elsanosi R, Bani I, Ageely H, Milaat W, El-Najjar M, Makeen A, Yagob U: Socio-medical problem of the habituation of Khat chewing in Jazan region in Southern Saudi Arabia. Eur J Sci Res 2011, 63: 122–133.
35.
McClave AK, Dube SR, Strine TW, Mokdad AH: Associations between health-related quality of life and smoking status among a large sample of US adults. Prev Med 2009, 48: 173. 10.1016/j.ypmed.2008.11.012CrossRefPubMed
36.
Guyatt GH, Feeny DH, Patrick DL: Measuring health-related quality of life. Ann Int Med 1993, 118: 622. 10.7326/0003-4819-118-8-199304150-00009CrossRefPubMed
37.
Julious SA, George S, Campbell MJ: Sample sizes for studies using the short form 36 (SF-36). J Epidemiol Community Health 1995, 49: 642. 10.1136/jech.49.6.642PubMedCentralCrossRefPubMed
38.
Walters SJ: Sample size and power estimation for studies with health related quality of life outcomes: a comparison of four methods using the SF-36. Health Qual Life Outcomes 2004, 2: 26. 10.1186/1477-7525-2-26PubMedCentralCrossRefPubMed
39.
National Toxicology Program: NTP Toxicology and Carcinogenesis Studies of Pentaerythritol Tetranitrate (CAS No. 78–11–5) with 80% D-Lactose Monohydrate (PETN, NF) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 1989, 365: 1–190.
40.
Substance Abuse Research Center (SARC): Cigarette smoking as a risk factor in men with a prior history of myocardial infarction. J Chronic Dis 1979, 32: 415–425.CrossRef
41.
Fischer W: Are DRGs homogeneous with regard to resource consumption. Paper Presented at the 16th Annual PCS/E Conference, Washington, DC 2000.
42.
Palmer G, Reid B: Evaluation of the performance of diagnosis-related groups and similar casemix systems: methodological issues. Health Serv Manage Res 2001, 14(2):71–81. 10.1258/0951484011912564CrossRefPubMed
43.
Cox G, Rampes H: Adverse effects of khat: a review. Adv Psychiatr Treat 2003, 9: 456–463. 10.1192/apt.9.6.456CrossRef
44.
Khantzian EJ: The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997, 4(5):231–244. 10.3109/10673229709030550CrossRefPubMed
45.
Boys A, Marsden J, Strang J: Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res 2001, 16: 457–469. 10.1093/her/16.4.457CrossRefPubMed
46.
Elmi AS: The chewing of khat in Somalia. J Ethnopharmacol 1983, 8: 163–176. 10.1016/0378-8741(83)90052-1CrossRefPubMed
47.
Hansen P: The ambiguity of khat in Somaliland. J Ethnopharmacol 2010, 132: 590–599. 10.1016/j.jep.2010.02.028CrossRefPubMed
48.
Wedegaertner F, Al-Warith H, Hillemacher T, Te Wildt B, Schneider U, Bleich S, Breitmeier D: Motives for khat use and abstinence in Yemen-a gender perspective. BMC Public Health 2010, 10: 735. 10.1186/1471-2458-10-735PubMedCentralCrossRefPubMed
49.
Hawkins JD, Lishner DM, Catalano RF: Childhood predictors and the prevention of adolescent substance abuse. NIDA Res Monogr 1985, 56: 75–126.PubMed
50.
Steinberg L: Adolescent transitions and alcohol and other drug use prevention. Preventing Adolescent Drug Use: From Theory to Practice 1991, 13–51.
51.
Richardson L, Wood E, Li K, Kerr T: Factors associated with employment among a cohort of injection drug users. Drug Alcohol Rev 2010, 29: 293–300. 10.1111/j.1465-3362.2009.00141.xCrossRefPubMed
52.
Manghi RA, Broers B, Khan R, Benguettat D, Khazaal Y, Zullino DF: Khat use: lifestyle or addiction? J Psychoactive Drugs 2009, 41: 1–10. 10.1080/02791072.2009.10400669CrossRefPubMed
53.
Corkery JM, Schifano F, Oyefeso A, Ghodse AH, Tonia T, Naidoo V, Button J: Overview of literature and information on" khat-related" mortality: a call for recognition of the issue and further research. Ann Ist Super Sanita 2011, 47: 445–464.PubMed
54.
Galea S, Vlahov D: Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep 2002, 117: S135.PubMedCentralPubMed
55.
Torrance N, Smith BH, Lee AJ, Aucott L, Cardy A, Bennett MI: Analysing the SF‒36 in population‒based research A comparison of methods of statistical approaches using chronic pain as an example. J Eval Clin Pract 2009, 15: 328–334. 10.1111/j.1365-2753.2008.01006.xCrossRefPubMed
56.
Daeppen JB, Krieg MA, Burnand B, Yersin B: MOS-SF-36 in evaluating health-related quality of life in alcohol-dependent patients. Am J Drug Alcohol Abuse 1998, 24: 685–694. 10.3109/00952999809019617CrossRefPubMed
57.
Heslin KC, Stein JA, Heinzerling KG, Pan D, Magladry C, Hays RD: Clinical correlates of health-related quality of life among opioid-dependent patients. Qual Life Res 2011, 20: 1205–1213. 10.1007/s11136-011-9858-yPubMedCentralCrossRefPubMed
58.
Colpaert K, De Maeyer J, Broekaert E, Vanderplasschen W: Impact of addiction severity and psychiatric comorbidity on the quality of life of alcohol-, drug-and dual-dependent persons in residential treatment. Eur Addict Res 2013, 19: 173–183. 10.1159/000343098CrossRefPubMed
59.
Cayuela A, Rodríguez-Domínguez S, Otero R: Deteriorated health-related quality of life in healthy male smokers. Archivos de Bronconeumología ((English Edition)) 2007.
60.
McHorney CA, Ware JE Jr, Raczek AE: The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuringphysical and mental health constructs. Med Care 1993, 31(3):247–263. 10.1097/00005650-199303000-00006CrossRefPubMed
61.
Dhadphale M, Omolo O: Psychiatric morbidity among khat chewers. East Afr Med J 1988, 65: 355–359.PubMed
62.
Critchlow S, Seifert R: Khat-induced paranoid psychosis. Br J Psychiatry 1987, 150: 247–249. 10.1192/bjp.150.2.247CrossRefPubMed
63.
Alem A, Shibre T: Khat induced psychosis and its medico-legal implication: a case report. Ethiop Med J 1997, 35: 137.PubMed
64.
Pantelis C, Hindler CG, Taylor JC: Use and abuse of khat (Catha edulis): a review of the distribution, pharmacology, side effects and a description of psychosis attributed to khat chewing. Psychol Med 1989, 19: 657–668. 10.1017/S0033291700024259CrossRefPubMed
65.
Brenneisen R, Fisch H, Koelbing U, Geisshusler S, Kalix P: Amphetamine‒like effects in humans of the khat alkaloid cathinone. Br J Clin Pharmacol 2012, 30: 825–828.CrossRef
66.
James Giannini A, Castellani S: A manic-like psychosis due to Khat Catha edulis Forsk. Clin Toxicol 1982, 19: 455–459. 10.3109/15563658208992500
67.
Streiner DL, Norman GR: Health Measurement Scales: A Practical Guide to their Development and Use. USA: Oxford University Press; 2008.CrossRef
Metadata
Title
Khat chewing and health related quality of life: cross-sectional study in Jazan region, Kingdom of Saudi Arabia
Authors
Kamaludin Ahmed Sheikh
Maged El-setouhy
Umar Yagoub
Rashad Alsanosy
Zafar Ahmed
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2014
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-12-44

Other articles of this Issue 1/2014

Health and Quality of Life Outcomes 1/2014 Go to the issue

Research

Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis

Research

Measuring the psychosocial burden in women with low-grade abnormal cervical cytology in the TOMBOLA trial: psychometric properties of the Process and Outcome Specific Measure (POSM)

Review

Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures

Review

Interviewing to develop Patient-Reported Outcome (PRO) measures for clinical research: eliciting patients’ experience

Research

Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study

Research

Psychometric study of the Persian short-form eight-item Parkinson’s disease questionnaire (PDQ-8) to evaluate health related quality of life (HRQoL)